* Metacrine Inc MTCR.PK is expected to report results on
March
28 (estimated).
*
* Refinitiv's mean analyst estimate for Metacrine Inc is
for a
loss of 14 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Metacrine
Inc is
$0.5, below its last closing price of $0.57.
This summary was machine generated March 24 at 22:29 GMT. All
figures in US dollars unless otherwise stated